uniQure kondigt een update aan van Fase I/II klinische studies met AMT-130 gentherapie voor de behandeling van de ziekte van Huntington
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean CSF NfL continue to demonstrate favorable trends with low-dose patients below baseline at 30 months and high-dose patients near baseline Lees meer...